TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06461429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine citrate: Medium dose
Description: Medium dose caffeine: 30mg/kg load and 15 mg/kg/day maintenance. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine citrate: High dose
Description: Higher dose caffeine: 40mg/kg load and 20mg/kg/day maintenance. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.
Study: NCT05445934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001
Description: FB2001 for injection will be reconstituted with 100 mL of normal saline prior to intravenous infusion. FB2001 will be administered by IV infusion over approximately 60 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FB2001 placebo
Description: Placebo will be reconstituted with 100 mL of normal saline prior to intravenous infusion. Placebo will be administered by IV infusion over approximately 60 minutes.
Study: NCT05366673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Description: Perform a 10-minute back massage every day for a week
Study: NCT04323566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 500 mg, dissolved in 250 ml NaCl in an infusion bag, covered with non-see-through plastic~* administered iv over a course of max 180 minutes~* at 0 and 4 months (treatment-first arme) OR at 8 and 12 months (placebo-first arm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 500 mg, dissolved in 250 ml NaCl in an infusion bag, covered with non-see-through plastic~* administered iv over a course of max 180 minutes~* at 0 and 4 months (treatment-first arme) OR at 8 and 12 months (placebo-first arm)
Study: NCT05966376

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemostatic device for distal radial approach.
Description: Hemostasis after distal radial approach is done with one of two devices, one of them is designed specifically for the distal radial approach; the other is not but a modified technique with the last one could be helpful.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemostatic device for distal radial approach.
Description: Hemostasis after distal radial approach is done with one of two devices, one of them is designed specifically for the distal radial approach; the other is not but a modified technique with the last one could be helpful.
Study: NCT05292196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC3721 suspension for inhalation
Description: TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor
Study: NCT05144334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX-1188
Description: One 28 day cycle of treatment will consist of 4 weeks of treatment with BTX-1188 administered orally per dosing schedule.
Study: NCT05292196

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQC3721 suspension placebo for inhalation
Description: TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor
Study: NCT05144334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX-1188
Description: One 28 day cycle of treatment will consist of 4 weeks of treatment with BTX-1188 administered orally per dosing schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX-1188
Description: One 28 day cycle of treatment will consist of 4 weeks of treatment with BTX-1188 administered orally per dosing schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX-1188
Description: One 28 day cycle of treatment will consist of 4 weeks of treatment with BTX-1188 administered orally per dosing schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX-1188
Description: One 28 day cycle of treatment will consist of 4 weeks of treatment with BTX-1188 administered orally per dosing schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX-1188
Description: One 28 day cycle of treatment will consist of 4 weeks of treatment with BTX-1188 administered orally per dosing schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX-1188
Description: One 28 day cycle of treatment will consist of 4 weeks of treatment with BTX-1188 administered orally per dosing schedule.
Study: NCT06029530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine Ophthalmic
Description: eye drops to be administered once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine Ophthalmic
Description: eye drops to be administered once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine Ophthalmic
Description: eye drops to be administered once daily
Study: NCT05823558

Intervention type: DIAGNOSTIC_TEST
Intervention: Lomber Muscle Thickness Measurement
Description: Muscle thickness measurements will be made on the imaging of those who have lumbar MR imaging.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lomber Muscle Thickness Measurement
Description: Muscle thickness measurements will be made on the imaging of those who have lumbar MR imaging.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lomber Muscle Thickness Measurement
Description: Muscle thickness measurements will be made on the imaging of those who have lumbar MR imaging.
Study: NCT06431542

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: physician-applied Triamcinolone Acetonide Econazole Cream
Description: The doctor applies the Triamcinolone Acetonide Econazole Cream onto a thin cotton swab and gently inserts it deep into the ear canal, evenly spreading the cream around the sides of the ear canal and on the surface of the eardrum.
Study: NCT05813834

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Genicular Nerves Block
Description: US guided genicular nerves block
Study: NCT06431542

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: patient-applied Triamcinolone Acetonide Econazole Cream
Description: The patient applies Triamcinolone Acetonide Econazole Cream in the external auditory canal at home using a cotton swab.
Study: NCT05347459

Intervention type: DRUG
Intervention: Dapagliflozin
Description: usual and customary doses for type 2 diabetes management

Intervention type: DRUG
Intervention: Empagliflozin
Description: usual and customary doses for type 2 diabetes management

Intervention type: DRUG
Intervention: Canagliflozin
Description: usual and customary doses for type 2 diabetes management

Intervention type: DRUG
Intervention: Sitagliptin
Description: usual and customary doses for type 2 diabetes management

Intervention type: DRUG
Intervention: Saxagliptin
Description: usual and customary doses for type 2 diabetes management

Intervention type: DRUG
Intervention: Linagliptin
Description: usual and customary doses for type 2 diabetes management

Intervention type: DRUG
Intervention: Vildagliptin
Description: usual and customary doses for type 2 diabetes management
Study: NCT05490563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLS-005
Description: SLS-005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLS-005
Description: SLS-005

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (sodium chloride injection, 0.9%, USP)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (sodium chloride injection, 0.9%, USP)
Study: NCT06345053

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy
Description: The intervention period will be from (May 2021- October 2024). All patients will participate in standard treatment at MBS. Dialectical Behaviour Therapy -Substance Use Disorder skills training (DBT-SUD skills) will be offered to all patients at MBS in the project period that experience difficulties in emotion regulation and manage to commit to participating in the DBT- skills training evaluated by their DBT therapist. Narrative Exposure Therapy (NET) will be offered to all patients with relevant traumatic experience and symptoms of PTSD depending on clinical evaluation.
Study: NCT04130906

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Theta Burst Stimulation
Description: iTBS will be delivered to the left dorsolateral prefrontal cortex (DLPFC) at 80% of resting motor threshold using standard stimulation parameters; triplet-bursts will be delivered at high frequency (50 Hz) with an inter-burst interval of 200 ms. Each TBS train will last 2 seconds and consists of 10 triplet-bursts (30 pulses). Each iTBS session will involve 10 TBS trains repeated every 10 seconds for 190 seconds, with a total number of 600 pulses delivered during each session.
Study: NCT06260150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Pneumatic Compression Devices
Description: During use, the pressure is gradually reduced from large to small, and pressure is applied in steps, starting from the calf and moving up to the thigh. Every 30 minutes, the patient's skin color of the lower extremities is observed for any abnormalities, and the blood supply status of the distal ends of both lower limbs (palpation of the dorsalis pedis artery pulse) is noted. If any special conditions occur, the procedure must be immediately stopped.
Study: NCT04130906

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Intermittent Theta Burst Stimulation
Description: Sham stimulation will be delivered left dorsolateral prefrontal cortex (DLPFC) using the same parameters as real iTBS however, a sham coil will be used. The sham coil makes the same noise and creates a similar sensation on the scalp as the real coil but does not produce a magnetic field.
Study: NCT05976815

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Aerobic and Resistance Exercise
Description: Apart from the neoadjuvant chemotherapy treatment (standard of care), participants allocated to the experimental group will additionally participate in a supervised physical exercise program that comprises 3 weekly sessions during the months that the patient is undergoing chemotherapy treatment. Each 75-minute session will comprise a 10-minute warm up, 30 minutes of strength training involving exercise for the major muscle groups, 30 minutes of aerobic training at 40-89% of heart rate reserve and a 5-minute cool down.
Study: NCT05319405

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sana Device
Description: Externally worn mask that physically contacts the skin of the face. The Sana Device delivers Audio Visual Stimulation (AVS) in the form of coordinated pulses of light (through closed eyelids) and sound at various frequencies.
Study: NCT06192355

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic hemostasis using a Esophagogastroduodenoscopy
Description: performing an Esophagogastroduodenoscopy for diagnosis and therapy of possible bleeding sites
Study: NCT05154162

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSMA PET/CT
Description: PSMA PET/CT (limited to the pelvis)
Study: NCT06192355

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic hemostasis using a Esophagogastroduodenoscopy
Description: performing an Esophagogastroduodenoscopy for diagnosis and therapy of possible bleeding sites
Study: NCT05154162

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transperineal template prostate biopsy
Description: Transperineal template prostate biopsies will be performed as per treating urologist's usual practice. No specific template for biopsy is prescribed for the purposes of the study. However, template sampling of the prostate is required, with a minimum of 12 cores, dependent on prostate volume. MRI will be available for any additional targeted biopsies required. Transperineal template biopsies must be labelled appropriately and sent for histopathological analysis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transperineal targeted prostate biopsy
Description: If the PSMA PET/CT is normal, transperineal prostate biopsy would be omitted If the PSMA PET/CT is abnormal, transperineal prostate biopsies would be performed targeting the MRI (done prior to study) and PSMA PET/CT images
Study: NCT05266040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 MG
Description: Consistent with the pilot study VEII will use a random number generator to randomly assign a Manila packet containing amoxicillin 500mg + Valtrex (valacyclovir 500mg x three times daily for 7 days). Opaque medication packaging and using standardized verbal and written instructions helps ensure blindness of the VEII calibrated clinician, and patients of the therapeutic group they were assigned to.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Consistent with the pilot study VEII will use a random number generator to randomly assign a Manila packet containing amoxicillin 500mg + Placebo (empty capsule). Opaque medication packaging and using standardized verbal and written instructions helps ensure blindness of the VEII calibrated clinician, and patients of the therapeutic group they were assigned to.
Study: NCT04678869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: prophylactic ciprofloxacin (10mg/kg BD, enteral/IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic
Description: Standard of care antibiotic as per local policy
Study: NCT05631925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol bolus
Description: Propofol will be added in bolus doses of 0.5mg/kg.
Study: NCT04613570

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Upper gastrointestinal endoscopy
Description: In all patient's complete gastroscopy first with White light and then with virtual chromoendoscopy will be made;~* Suspicious lesions with dysplasia/cancer will be biopsied 1-2 fragments in a different vial; if an irregular area of mucosa (pattern C) with no clearly defined lesion then 1-2 guided biopsies fragments will be taken and sent in a different vial;~* EGGIM (Endoscopic Grading of Gastric Intestinal Metaplasia) will be calculated according to previous description of this classification:~* If EGGIM 0 (no endoscopically apparent IM) biopsies will be made in antrum, incisura and corpus according to Sydney-Houston protocol;~* If EGGIM 1 or more guided biopsies of suspicious areas of IM should be made replacing the random biopsies in that particular area;~* Antrum, incisura and corpus fragments should be sent in 3 separate vials;

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Upper gastrointestinal endoscopy
Description: In all patient's complete gastroscopy first with White light and then with virtual chromoendoscopy will be made;~* Suspicious lesions with dysplasia/cancer will be biopsied 1-2 fragments in a different vial; if an irregular area of mucosa (pattern C) with no clearly defined lesion then 1-2 guided biopsies fragments will be taken and sent in a different vial;~* EGGIM (Endoscopic Grading of Gastric Intestinal Metaplasia) will be calculated according to previous description of this classification:~* If EGGIM 0 (no endoscopically apparent IM) biopsies will be made in antrum, incisura and corpus according to Sydney-Houston protocol;~* If EGGIM 1 or more guided biopsies of suspicious areas of IM should be made replacing the random biopsies in that particular area;~* Antrum, incisura and corpus fragments should be sent in 3 separate vials;
Study: NCT05631925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol infusion
Description: Propofol will be administered as 10mg/kg/hour infusion.
Study: NCT06163235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Obemar platform
Description: Online platform for education and follow-up
Study: NCT06193083

Intervention type: OTHER
Intervention: Semi-directed individual interviews
Description: Individual semi-structured interviews (descriptive approach methodology with reflexive thematic analysis)

Intervention type: OTHER
Intervention: The self-administered questionnaires, rPATD and BMQ
Description: rPATD: The rPATD is a questionnaire validated and adapted in French to assess patients' perceptions of their treatments and deprescribing.~This self-administered questionnaire consists of 22 questions rated on a 5-point Likert scale (scale from 1 to 5, at 1 the patient completely agrees with the questionnaire's proposal, at 5 the patient strongly disagrees with the questionnaire's proposal)~BMQ French version of the BMQ self-questionnaire, which studies patients' perceptions of medication .~The Beliefs about Medicine Questionnaire (BMQ) is an 18-item self-administered questionnaire designed to explore patient perceptions of medicine. It has been validated in French and is free to use.~It comprises 10 items relating to specific beliefs about prescribed treatments:~A 5-point Likert-type scale was used for each item. The higher the sum of the scores obtained, the stronger the subject's belief.

Intervention type: OTHER
Intervention: The self-administered FCCHL (Functional, Communicative and Critical Health Literacy) / HLS14 (14-item health literacy scale)
Description: FCCHL (Functional, Communicative and Critical Health Literacy)/HLS14 (14-item health literacy scale) (https://reflis.fr/wp-content/uploads/2020/07/FCCHL-HLS14-Questionnaire-Litteratie-sante.pdf )~Validated French-language self-administered questionnaire and consisting of14 items with a 5-point Likert scale for assessing health literacy :~Functional literacy: basic reading and writing skills sufficient to function effectively in everyday situations Communicative or interactive literacy: more advanced cognitive and literacy skills that, combined with social skills, can be used to actively participate in everyday activities, extract information and meanings from different forms of communication, and apply new information to changing circumstances Critical literacy: more advanced cognitive skills which, combined with social skills, can be applied to the critical analysis of information and the use of that information to exercise greater control over life events and situations
Study: NCT05295329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Danshen Dropping Pills
Description: use Compound Danshen Dropping Pills

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: use placebo
Study: NCT06626737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (DAPA)
Description: Participants will take Dapagliflozin 10mg every day in -1 to 14 days
Study: NCT06406816

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Neoantigen Vaccine plus Capecitabine
Description: 1. Capecitabine.Twice a day, 30 minutes after breakfast, swallow with water, continue for 2 weeks, then stop for 1 week, constitutes one cycle; three weeks make one cycle, lasting for 8 cycles.~2. Neoantigen Vaccine . Every 3 weeks, once every 21 days, for 4 to 8 cycles. The injection is administered on the first day after cessation of capecitabine. Treatment can last for up to 6 months without occurrences such as the researcher determining no further clinical benefit, intolerable toxic reactions, initiation of new anti-tumor treatment, withdrawal of informed consent, loss to follow-up, death, or other circumstances specified in the protocol that require treatment termination.
Study: NCT05036538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention with natural sounds administered via headphones
Description: The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with nature sounds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention with natural sounds and binaural beats administered via headphones
Description: The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with nature sounds and binaural beats.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention with natural sounds and virtual reality administered via headphones and head mounted display
Description: The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with a nature scene in a spherical 360° environment with associated nature sounds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention with natural sounds, binaural beats and virtual reality administered via headphones and head mounted display
Description: The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with a nature scene in a spherical 360° environment with associated nature sounds and binaural beats.
Study: NCT04883073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of Endo App
Description: Use of Endo App
Study: NCT04685330

Intervention type: PROCEDURE
Intervention: Ultrasound guided procedure
Description: Single-arm, open-label device efficacy study to enroll 200 patients who have been ordered to have an ultrasound-guided procedure by the MGH Interventional Radiology department, including paracentesis, thoracentesis, biopsy, or ultrasound-guided drain placement. Patients will be restricted to adults who can consent.

Intervention type: DEVICE
Intervention: Portable ultrasound
Description: The FDA approved Healcerion SONON portable ultrasound (linear and curved) will be used during clinically indicated standard ultrasound-guided procedures following clinical standard of care. A standard clinical ultrasound will subsequently be used for image guidance as the gold standard. Images will be compared and improved. The efficacy of the portable ultrasound will be monitored by the clinical user and any complications within 30 days will be determined by chart review.
Study: NCT05379140

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Three Weekly Therapeutic Chinese Massage Sessions
Description: Participants in the therapeutic Chinese massage group received three weekly 25-minute therapeutic Chinese massage sessions. The intervention included acupressure to points along the distal lower extremity acupuncture points of the Gall Bladder Channel (GB 40 and then 34). Further Chinese Massage incorporates kneading, rolling, movement of the ankle, rotating, pulling, and scrubbing to the lower extremity.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Three Weekly Placebo Massage Sessions
Description: The placebo massage group received three weekly 25-minute placebo massage that included gentle rubbing to the foot and toes without point stimulation or other techniques of Chinese Massage. The control group had the opportunity to receive the treatment after the study was completed.
Study: NCT05697432

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oral Examination
Description: A complete examination of oral and dental hygiene any health problems will be registered

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PUFA index
Description: An assessment of the presence of oral conditions resulting from untreated caries. P=Pulpal involvement, U=ulceration, F=fistula, A=abscess index